Scarica l'app Stockscreener
20.36
1.78%
-0.37
Dopo l'orario di chiusura:
20.55
0.19
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BAX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Baxter International Inc Borsa (BAX) Ultime notizie
Baxter International Inc To Go Ex-Dividend On February 27th, 2026 With 0.01 USD Dividend Per Share - 富途牛牛
Ex-Dividend Reminder: MGE Energy, Labcorp Holdings and Baxter International - Nasdaq
Infusion Stand Market Is Going to Boom | BD • Baxter International • Smiths Medical - openPR.com
Baxter Investors Face a Test of Patience Amid Corporate Overhaul - AD HOC NEWS
Is Baxter International (BAX) Pricing In Its Turnaround After Years Of Share Price Weakness? - simplywall.st
Baxter International's $3 Billion Sales Base Facing Earnings Pressure - Smartkarma
Baxter is one of the S&P 500’s worst performers today. Earnings were brutal. - MSN
Baxter’s Ongoing Losses And Impairments Test The Investment Narrative - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Through Challenges with Strategic Resilience - DirectorsTalk Interviews
Is Baxter International Inc (BAX) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Baxter Hopes Recovery Under New CEO, Faces Near-Term Pressure - Citeline News & Insights
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading - Yahoo Finance
Patient Lifting Equipment Market is Going to Boom | Baxter International Inc., ICU Medical, Inc., B. Braun Melsungen AG - openPR.com
The Top 5 Analyst Questions From Baxter's Q4 Earnings Call - Finviz
Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider - GlobeNewswire Inc.
Benefits of Device Connectivity - Baxter
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Anti-Venom Market 2026-2035 Top Key Playres: Baxter - openPR.com
Demystifying Baxter International: Insights From 4 Analyst Reviews - Benzinga
Baxter International Inc (BAX) Shares Up 3.99% on Feb 17 - GuruFocus
BAX: Goldman Sachs Lowers Price Target on Baxter International | - GuruFocus
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case - Sahm
Baxter International (BAX) Returns To Quarterly Loss And Tests Earnings Recovery Narrative - Sahm
Aug Sectors: Is Baxter International Inc a potential multi baggerJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
UBS Maintains Neutral on BAX Baxter International Inc. Feb 2026 - Meyka
Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment - Yahoo Finance
Baxter’s New Decentralized Model Tests Earnings And Valuation Expectations - Yahoo Finance
Quarterly Trades: Does Baxter International Inc outperform in volatile marketsTrend Reversal & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Baxter International Stock Was Tumbling Today - AOL.com
Is Baxter International Inc. stock a top momentum playJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - mfd.ru
Is Baxter International Inc. stock a momentum leaderJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Baxter Overhaul Shifts To Decentralized Model As Recovery Timelines Extend - simplywall.st
Is Baxter International Inc. stock risky to hold nowProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Product Playbook - AD HOC NEWS
Baxter International (NYSE:BAX) Price Target Lowered to $17.00 at The Goldman Sachs Group - MarketBeat
A Quick Look at Today's Ratings for Baxter International Inc(BAX.US), With a Forecast Between $20 to $25 - 富途牛牛
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
The Truth About Baxter International Inc.: Hidden Healthcare Giant or Total Snooze Stock? - AD HOC NEWS
Baxter lays off 90 employees from hurricane-hit unit - Medical Buyer
Baxter International Earnings Call: Growth Meets Margin Squeeze - The Globe and Mail
BAX Q4 Deep Dive: Mixed Segment Performance and Margin Pressures Shape Outlook - Finviz
Looking Into Baxter International Inc's Recent Short Interest - Benzinga
Barclays Lowers Price Target for Baxter Intl (BAX) While Maintai - GuruFocus
Jefferies Financial Group Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Barclays Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter sales up 8% to USD 2.97B in Q4 2025 - Medical Buyer
Baxter International Inc. (NYSE:BAX) Plans Quarterly Dividend of $0.01 - MarketBeat
Baxter International Inc. (NYSE:BAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Baxter International Inc. (NYSE:BAX) Q4 2025 earnings call transcript - MSN
LSV Asset Management Decreases Stake in Baxter International Inc. $BAX - MarketBeat
Baxter's new CEO mired in damage control before he can address long-term problems - Crain's Chicago Business
Baxter International Inc (BAX) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures - GuruFocus
Baxter International Inc. stock underperforms Thursday when compared to competitors - MSN
Baxter Stock (-16%): Profit Guidance Collapse Triggers De-Risking - Trefis
Decoding Baxter International Inc (BAX): A Strategic SWOT Insigh - GuruFocus
Baxter International Is Quietly Going Off – But Is BAX Stock Really Worth Your Money? - AD HOC NEWS
Baxter International (BAX) Q4 2025 Sales Exceed Expectations, EPS Falls Short - GuruFocus
BAXTER INTERNATIONAL INC SEC 10-K Report - TradingView
Baxter stock dives on Q4 EPS miss, company introduces new operating model - massdevice.com
Baxter (BAX) Q4 Earnings Miss, Revenue Surpasses Expectations - GuruFocus
2.48%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):